Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2025-04-28 Report Publication Anno…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF ANNUAL REPORT 2024 AND ENVIRONMENT, SOCIAL AND GOVERNANCE REPORT
Report Publication Announcement Classification · 95% confidence The document is a notification letter titled “Notice of Publication of Annual Report 2024 and Environment, Social and Governance Report,” informing non-registered shareholders that the Company’s annual report and ESG report have been published on its website and HKEXnews, and explaining how to request printed copies. It does not contain the full report content itself but merely announces its publication. This matches the definition of a Report Publication Announcement (RPA).
2025-04-28 English
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF ANNUAL REPORT 2024 AND ENVIRONMENT, SOCIAL AND GOVERNANCE REPORT
Report Publication Announcement Classification · 95% confidence The document is a letter notifying shareholders of the publication of the company’s 2024 Annual Report and ESG Report and explaining how they may access or request printed copies. It does not contain the actual report content or detailed financial disclosures itself but rather serves as a notice of publication and instructions for receiving future corporate communications. This matches the definition of a Report Publication Announcement (RPA).
2025-04-28 English
2024 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2024' and contains comprehensive sections including financial highlights, management discussion and analysis, directors' report, corporate governance, and full consolidated financial statements (profit or loss, financial position, cash flow). It is a full-year statutory report for Simcere Pharmaceutical Group Limited, fitting the definition of a 10-K (Annual Report). FY 2024
2025-04-28 English
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 98% confidence The document is a comprehensive Environmental, Social and Governance (ESG) Report for 2024, containing detailed sections on governance structure, ESG targets, stakeholder engagement, environmental management, social responsibility programs, UN SDGs, performance metrics and more. It matches the definition of an Environmental & Social Information report (Code: SR) rather than an announcement or summary. It is not just a notice of publication, nor an Annual Report or Interim Report, but a standalone ESG report covering environmental, social and governance practices.
2025-04-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 94% confidence The document is a Hong Kong Stock Exchange Form FF305 "Next Day Disclosure Return" relating exclusively to changes in issued shares and treasury shares (including detailed repurchase transactions on the Exchange, volumes, prices, cancellation and treasury share balances). This is a report of the company’s own share transactions (buybacks and treasury share movements), matching our definition for "Transaction in Own Shares (POS)".
2025-04-16 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a Next Day Disclosure Return (Form FF305) under Hong Kong Listing Rules, detailing changes in issued shares and treasury shares specifically reporting a series of share repurchases (on-market buybacks) including dates, volumes, and prices. This is a report of the company buying back its own shares, which corresponds to the “Transaction in Own Shares” category.
2025-04-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.